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Conclusion
The diagnosis of PAEF/PADF is difficult and
sometimes not made until exploratory laparotomy. A delay
in its identification, which is rather common, may partly
explain the high mortality. The diagnosis should be
considered not only in any patient known to have an
abdominal aortic aneurysm but also in a patient who
presents with lower abdominal pain associated with a
midline mass and exhibits upper gastrointestinal bleeding
when no other source of bleeding is seen on OGD. 
Learning Points 
The diagnosis of primary aortoenteric fistula should
be considered in any patient known to have abdominal
aortic aneurysm or lower abdominal pain associated with
midline mass and upper gastrointestinal bleeding of
unexplained aetiology.
A "herald bleeding" is an opportunity for prompt
intervention Endoscopy is the first step in diagnosis.
Computed tomography may confirm the diagnosis.
Emergency exploratory laparotomy should be done
as soon as the diagnosis is considered.
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Opinion and Debate
Glucose-6-phosphate dehydrogenase (G6PD) screening in Pakistani neonates: 
To be or not to be……
Bushra Moiz
Department of Pathology and Microbiology, The Aga Khan University, Karachi.
The primary metabolic role of erythrocyte glucose-
6-phosphate dehydrogenase (G6PD) is the protection of red
cells against oxidative damage. Its deficiency is the
commonest inherited red cell enzymopathy as it affects
around 400 million people globally with the highest
prevalence in tropics and subtropics. Because it is an X-
linked disorder, hemizygous males and homozygous
females are the ones that are mainly affected. However,
approximately 10% of heterozygous females may also be at
risk. The presentation is variable depending on the residual
enzyme activity and ranges from completely asymptomatic
individuals to those who have life long haemolysis. Most
significant manifestations are drug-induced haemolysis,
favism, neonatal hyper bilirubinaemia and non spherocytic
haemolytic anaemia.1
There is considerable evidence to believe that G6PD
deficiency in Pakistan is not a rarity as various population
based studies have shown a prevalence ranging from 2-
3.8%2-5 with highest frequency of 8.6% observed in
Pathans.6 Unfortunately, there is no documentation of
characterization of its biochemical variants. Moreover,
other than a single contribution from Saha et al7 which
identified presence of 563C-T and silent mutation of 1311
C-T in Pashtoons and Punjabis, nothing is known about the
patterns and prevalence of different disease-causing
mutations in the various Pakistani ethnic groups. 
Infants with severe variants of G6PD deficiency are
known to develop hyperbilirubinaemia that may be
sufficient to cause kernicterus and even death.1 Recent
research is focusing on decreased bilirubin conjugation
rather than haemolysis as the primary aetiology for neonatal
jaundice (NNJ) in the enzyme deficient babies with
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promoter polymorphism of UDP glucoronyl transferase
1A1 gene (UGT1A1) as the major implicating factor. 
To evaluate the magnitude of the problem at the
national level, the author explored various local and
international search engines. Several single institution based
studies conducted at Peshawar and Lahore had shown an
incidence of G6PD deficiency varying from 4 to 14% in
jaundiced neonates.8,9 All babies developed
hyperbilirubinaemia within 0-5 days of their birth with
serum bilirubin reported to be as high as 50 mg /dL in some
babies. Phototherapy was required by all the infants with an
additional requirement of exchange transfusion in 6-65% of
patients. Unfortunately, a significant proportion of G6PD
deficient newborns (4-22%) developed kernicterus with
mortality ranging from 2-4.3%. 
Neonatal G6PD screening programs are enforced in
those areas of the world where severe variants of G6PD
deficiency are widespread such as Middle East, Eastern
Europe and Southeast Asia. These have shown promising
results in terms of avoiding acute haemolytic crisis and
permanent brain damage in babies.  Since the prevalence of
severe hyperbilirubinaemia among our neonates was
observed to be relatively high with exchange transfusion
required in a half of them, early detection of this
enzymopathy would be a viable option through mass
screening programmes.
Several factors need to be considered in evaluating
the feasibility, need and cost effectiveness of any neonatal
mass screening programmes: prevalence and severity of the
disease in target population, availability of inexpensive user
friendly screening tests, access to treatment and follow-ups.
According to world health fact sheet 2007, Pakistan
having a population of 165 million and growth rate of 1.8%
has the annual birth rate of 27.52 /1000. According to World
Health Organization (WHO), 53 neonates out of 1000 live
births die of various reasons in our country. The situation is
complex in terms of estimation of frequency of neonatal
jaundice as over 89 % of our babies are delivered in homes
and any organized data on routine health outcomes from
rural Pakistan is non existent. Because of these reasons, it is
impossible to estimate the burden of overall G6PD
deficiency in our country. There is dire need to carry out a
large epidemiological study of G6PD deficiency associated
neonatal hyperbilirubinemia to elucidate the true
dimensions of the problem. 
The author inferred from available documentation
that during the reporting duration of 22 years (1984 to 2006),
2811 neonates had hospital admissions because of neonatal
jaundice.  Of these, 256 babies (9.1%) screened positive for
G6PD defecieny.8,9 However, the data is skewed as all
studies were done either in Peshawar or at Lahore, which are
more likely to be inhabited by Pathans and Punjabis- the
ethnic groups that have been identified to be at risk. Needless
to say that similar results are expected as G6PD deficiency
has been reported in adults from all over the country. 
The International Committee for Standardization in
Haematology has recommended the fluorescent spot test as
a screening test for G-6-PD deficiency. However, some
recently published studies of G-6-PD deficiency in neonates
have utilized the commercial color reduction kit. The latter
test is cheaper, easier to perform, less time consuming, and
requires less sophisticated equipment (ultraviolet lamp)
than the fluorescent spot test. Later was utilized in the
studies reported so far from our country. Thus it may be
more appropriate for mass use in developing countries than
the more complicated fluorescent spot test. It can be set up
and run by unskilled workers in a doctor's office or
neighborhood clinic. The cost per test is estimated to be
$0.5-0.9 which is negligible when compared to the cost of
hospital admissions and exchange transfusions.
The mass screening for G6PD would be invaluable
in identifying the deficient babies at the time of their birth.
This can easily be achieved by saving cord blood and
performing the test on the sample without causing extra
discomfort to infant. Serial monitoring of bilirubin for such
babies would help in evaluating those infants who can not
be discharged from hospitals but appropriately managed
with adequate hydration, phototherapy and/or exchange
transfusion thus avoiding permanent brain damage. The
identification of deficient babies would aid the health
workers to counsel parents in avoiding exposure of their
babies and themselves (if lactating) to oxidizing agents, to
watch for jaundice and to bring jaundiced infant to hospital
at their earliest. The mothers can also be advised to check
for G6PD levels in other children. 
A major fallacy of this program would be failure to
diagnose female heterozygote babies as their enzyme levels
are enough to give a negative screening result. However,
evidence shows that 10% of them can suffer from severe
haemolysis, NNJ and kernicterus.10 The spectrophotometeric
quantification of enzyme is advisable in such circumstances
if there is strong clinical suspicion of enzyme deficiency in
female babies. It is of interest to note that our local data
showed 16 G6PD deficient female babies of a total of 252
enzyme deficient infants.8,9 It can be concluded that these
might represent severely affected homozygous females
detected on qualitative assays. 
For the screening program to be effective, we would
not only face the challenge of training doctors, nurses and
lady health workers for changing their beliefs and attitudes
but also monitoring home deliveries and training dais would
be a difficult task. 
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Our evaluation testifies the importance that initiation
of mass neonatal G6PD screening should be considered in
our country. It can avoid the incidence of permanent brain
damage resulting from hyperbilirubinemia with subsequent
kernicterus and death. Such measures can not only guide the
pediatricians for successful management of their patients
but also provide an opportunity to start comprehensive
educational programs for parents thus avoiding lifelong
morbidity of enzyme deficient individuals.      
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Student’s Corner
Letter to the Editor
Therapeutic Hypothermia: Keeping cool inside
Madam, "Time is tissue." This statement holds very
true when it comes to ischaemic and anoxic injuries of the
brain and cardiac tissue following cardiac arrest. Longer the
tissue remains in a state of ischaemia, more and more tissue
death and scarring occurs due to its continual oxygen
demand and ongoing metabolic activities. Once an episode
of heart attack occurs, damage to the heart tissue leads to
greatly reduced efficacy of the pump and increased risk of a
second attack and further damage. 
According to one study, one in four middle aged men
in Pakistan is a patient of coronary artery disease.1
Until recently, the only way to reduce the tissue
death in the first few crucial hours after the heart attack was
by medication. It is at this junction that the concept of tissue
cooling comes into play. The concept of cooling to preserve
tissue and aid healing is not a new one. Doctors have known
for more than a century that people who fall into icy water
have a better chance of survival than other drowning
victims. In some developing countries where operating
rooms are not equipped with bypass machines, patients are
still packed in ice during open heart surgery to stop all blood
flow. In one of its most recent applications, women
undergoing cancer treatments that often lead to infertility
can have their eggs cryogenically frozen for later use.
Therapeutic hypothermia is believed to work by
protecting critical tissues and organs such as the brain, heart
and kidneys following acute ischaemic or inflammatory
events, by lowering metabolism and preserving cellular
energy stores, thereby potentially stabilizing cellular
structure and preventing or reducing injuries at the cellular,
tissue and organ level.2
This theory has been put into practice, in many
developed countries, by inserting a temperature modulating
catheter via the femoral vein and onto the heart. Here ice
cold saline passes through the catheter, cooling the catheter
tip to 36 degrees. Blood flowing towards the heart is cooled
as it passes across the ice cold tip. Patient's body
temperature reaches the therapeutic hypothermic levels
quickly and stays that way for 24 hours. Demerol is given to
prevent shivering response to the decrease in body
temperature. The body is then rewarmed in the next 3 hours.
During the cold state the patient can undergo procedures
like angioplasty to unclog the blockage.3
This can stop the immediate or early myocardial
tissue destruction process or slow it down by decreasing its
metabolic activity and future scarring can be avoided.
The American Heart Association (AHA) recently
revised its treatment guidelines to recommend the use of
therapeutic cooling as part of the critical care procedures for
patients with an out-of-hospital cardiac arrest following
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